Details for Patent: 8,192,756

Which drugs does patent 8,192,756 protect, and when does it expire?

Patent 8,192,756 protects GRALISE and is included in one NDA.

This patent has twenty-four patent family members in nine countries.

Summary for Patent: 8,192,756

Title:	Gastric retained gabapentin dosage form
Abstract:	A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Inventor(s):	Berner; Bret (Half Moon Bay, CA), Hou; Sui Yuen Eddie (Foster City, CA), Gusler; Gloria M (Cupertino, CA)
Assignee:	Depomed, Inc. (Menlo Park, CA)
Application Number:	13/111,575
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,192,756
Patent Claim Types: see list of patent claims	Compound; Dosage form; Use;

Drugs Protected by US Patent 8,192,756

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Almatica	GRALISE	gabapentin	TABLET;ORAL	022544-001	Jan 28, 2011	BX	RX	Yes	Yes			Y			TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
Almatica	GRALISE	gabapentin	TABLET;ORAL	022544-002	Jan 28, 2011	BX	RX	Yes	Yes			Y			TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

International Family Members for US Patent 8,192,756

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002348828
Australia	2005267738
Australia	2006332690
Canada	2464322
Canada	2575555